Dr. Stadler is a clinical trialist focused on developing novel therapies and biomarkers, especially for genitourinary cancer. In addition to an extensive history performing trials in kidney, bladder, and prostate cancer, he also has broad experience in leading efforts supporting clinical trial infrastructure and conduct. These include renal cancer cadre leader for the Cancer and Leukemia Group B (CALGB, now Alliance), PI for a DOD funded prostate cancer clinical trials consortium, co-PI for a Prostate Cancer SPORE, PI for the NCI funded N01 contract for early phase clinical trials, and a current role as Dean for Clinical Research
University of Chicago
Chicago, IL
Postdoctoral Fellow - Oncology
1994
University of Chicago
Chicago, IL
Fellow - Oncology
1993
Michael Reese Hospital
Chicago, IL
Resident - Internal Medicine
1991
Yale University School of Medicine
New Haven, CT
MD - Medicine
1988
University of Illinois
Urbana, IL
BS - Chemistry
1984
Impact of postprogression therapies on overall survival: Recommendations from the 2023 kidney cancer association think tank meeting.
Impact of postprogression therapies on overall survival: Recommendations from the 2023 kidney cancer association think tank meeting. Urol Oncol. 2024 Nov 04.
PMID: 39500687
Primary site stereotactic ablative body radiotherapy in localized, recurrent, and metastatic renal cell carcinoma.
Primary site stereotactic ablative body radiotherapy in localized, recurrent, and metastatic renal cell carcinoma. Clin Transl Radiat Oncol. 2024 Nov; 49:100879.
PMID: 39529961
Feasibility of structuring electronic health record data to facilitate real-world data research: ICAREdata methods applied to multicenter cancer clinical trials.
Feasibility of structuring electronic health record data to facilitate real-world data research: ICAREdata methods applied to multicenter cancer clinical trials. Cancer. 2024 Aug 28.
PMID: 39192753
Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma.
Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma. N Engl J Med. 2024 Aug 22; 391(8):710-721.
PMID: 39167807
There Is More to Length of Survival Than Survival: Endpoints in Oncology Trials.
There Is More to Length of Survival Than Survival: Endpoints in Oncology Trials. Clin Cancer Res. 2024 Aug 01; 30(15):3098-3099.
PMID: 38767553
A Phase I Trial of Enzalutamide Plus Selective Glucocorticoid Receptor Modulator Relacorilant in Patients with Metastatic Castration-Resistant Prostate Cancer.
A Phase I Trial of Enzalutamide Plus Selective Glucocorticoid Receptor Modulator Relacorilant in Patients with Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2024 Jun 03; 30(11):2384-2392.
PMID: 38536082
Bladder-Preserving Trimodality Therapy With Capecitabine.
Bladder-Preserving Trimodality Therapy With Capecitabine. Clin Genitourin Cancer. 2024 04; 22(2):476-482.e1.
PMID: 38228414
Optimizing the doses of cancer drugs after usual dose finding.
Optimizing the doses of cancer drugs after usual dose finding. Clin Trials. 2024 Jun; 21(3):340-349.
PMID: 38148731
PROMISE Registry: A prostate cancer registry of outcomes and germline mutations for improved survival and treatment effectiveness.
PROMISE Registry: A prostate cancer registry of outcomes and germline mutations for improved survival and treatment effectiveness. Prostate. 2024 Feb; 84(3):292-302.
PMID: 37964482
Accelerator-Based Production of Scandium Radioisotopes for Applications in Prostate Cancer: Toward Building a Pipeline for Rapid Development of Novel Theranostics.
Accelerator-Based Production of Scandium Radioisotopes for Applications in Prostate Cancer: Toward Building a Pipeline for Rapid Development of Novel Theranostics. Molecules. 2023 Aug 13; 28(16).
PMID: 37630292